Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance

Diabetes

Volumn 52, Issue 2, 2003, Pages 453-462

  Garvey, W Timothy ^a,b,c   Kwon, Soonho ^a   Zheng, Deyi ^c   Shaughnessy, Sara ^a   Wallace, Penny ^a   Hutto, Amy ^a   Pugh, Kimberly ^a   Jenkins, Alicia J ^a   Klein, Richard L ^a,b   Liao, Youlian ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTERY DIAMETER; ARTICLE; DENSITY GRADIENT CENTRIFUGATION; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; BODY CONSTITUTION; BODY MASS INDEX; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MOLECULAR WEIGHT; REGRESSION ANALYSIS; SOUTH CAROLINA;

EID: 0037317156     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.2.453     Document Type: Article

References (50)

1. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473-486, 1995
2. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
3. Ferrannini E, Haffner SM, Mitchell BD, Stern MP: Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34:416-422, 1991
4. Laakso M: Insulin resistance and coronary heart disease. Curr Opin Lipidol 7:217-226, 1996
5. Austin MA, Breslow JL, HeMekens CH, Buring JE, Willet WC, Krauss RM: Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921, 1988
6. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276:875-881, 1996
7. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 95:69-75, 1997
8. Eckardstein A, Huang Y, Assmann G: Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 5:404-416, 1994
9. Tomkin GH, Owens D: Insulin and lipoprotein metabolism with special reference to the diabetic state. Diabetes Metab Rev 10:225-252, 1994
10. Taskinen MR: Hyperlipidaemia in diabetes. In Lipid and Lipoprotein Disorders, Baillieres Clinical Endocrinology and Metabolism. DJ Betteridge, Ed., Baillière Tindall, London, 1990, p. 743-755
11. Selby JV, Austin MA, Newman B, Zhang D, Quesenberry CP, Mayer EJ, Krauss RM: LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 88:381-387, 1993
12. Feingold KR, Grunfeld C, Coerrier W, Krauss RM: LDL subclass phenotypes and triglyceride metabolism in NIDDM. Arterioscler Thromb 12:1496-1502, 1992
13. Haffner SM, Mykkanen L, Robbin D, Valdez R, Howard BV, Stern MP, Bowsher R: A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects. Diabetologia 38:1328-1336, 1995
14. Barakat HA, Carpenter JW, McLendon VD, Khazanie P, Leggett N, Heath J, Marks R: Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition: possible link between hyperinsulinemia and atherosclerosis. Diabetes 39:1527-1533, 1990
15. Terry RB, Wood PD, Haskell WL, Stefanick ML, Krauss RM: Regional adiposity patterns in relation to lipids, lipoprotein cholesterol, and lipoprotein subfraction mass in men. J Clin Endocrinol Metab 68:191-199, 1989
16. Reaven GM, Chen Y-DI, Jeppesen J: Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 92:141-146, 1993
17. Festa A, D'Agostino R, Mykkanen L, Tracy R, Hales CN, Howard BV, Haffner SM: LDL particle size in relation to insulin, proinsulin, and insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22:1688-1693, 1999
18. Haffner SM, D'Agostino R, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF: Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22:562-568, 1999
19. Friedlander Y, Kidron M, Caslake M, Lamb Tracey, McConnell M, Bar-On H: Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis 148:141-149, 2000
20. Haffner S, D'Agostin R, Goff D, Howard B, Festa A, Saad M, Mykkänen L: LDL Size in Africans, Hispanics, and Non-Hispanic whites: Insulin Resistance Study. Arterioscler Thromb Vasc Biol 19:2234-2240, 1999
21. Austin MA, Selby JV: LDL subclass phenotypes and the risk factors of the insulin resistance syndrome. Int J Obes 19 (Suppl. 1):S22-S26, 1995
22. MacLean PS, Vadlamudi S, MacDonald KG, Pories W, Houmard J, Barakat HA: Impact of insulin resistance on lipoprotein subpopulation distribution in lean and morbidly obese nondiabetic women. Metab Clin Exp 49:285-292, 2000
23. Tilley-Kiesi M, Knudsen P, Groop L, Taskinen M-R, Botnia Study Group: Hyperinsulinemia and insulin resistance are associated with multiple abnormalities of lipoprotein subclasses in glucose tolerant relatives of NIDDM patients. J Lipid Res 37:1569-1578, 1996
24. Otvos JD, Jeyarajah EJ, Bennett, Krauss RM: Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 38:1632-1638, 1992
25. Otvos JD: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48:171-180, 2002
26. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA: Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 18:1046-1053, 1998
27. Rosenson RS, Freedman DS, Otvos JD: Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I) trial. Am J Cardiol 90:89-94, 2002
28. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R: Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterioseler Thromb Vasc Biol 22:1175-1180, 2002
29. Blake GJ, Otvos JD, Rifai N, Ridker PM: Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106:1930-1937, 2002
30. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 25 (Suppl. 1):S5-S20, 2002
31. Wojciechowski B, Willi SM, Berg JB, Wallace P, Ganaway E, Garvey WT: Toward rational diagnostic criteria for the insulin resistance syndrome. Diabetes 48 (Suppl. 1):A29, 1999
32. Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E, Pan Q, Garvey WT: The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 82:1293-1300, 1997
33. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234, 1985
34. Baron A, Laakso M, Brechtel G, Edelman SV: Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in noninsulindependent diabetic subjects. J Clin Invest 87:1186-1194, 1991
35. Rumsey SC, Galeano NF, Arad Y, Deckelbaum RJ: Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins. J Lipid Res 33:1551-1561, 1992
36. McNamara JR, Small DM, Li Z, Schaefer EJ: Differences in LDL: subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B. J Lipid Res 37:1924-1935, 1996
37. Grundy SM, Vega GL: Two different views of the relationship of hypertriglyceridemia to coronary heart disease: implications for treatment. Arch Intern Med 152:28-34, 1992
38. Stewart MW, Laker MF, Dyer RG, Gome F, Mitcheson J, Wincour H, Alberti KGMM: Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia. Arterioscler Thromb 13:1046-1052, 1993
39. Austin MA, King M-C, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart diseases risk. Circulation 82:495-506, 1990
40. Swinkels DW, Demacker PNM, Hendriks JCM, Van't Laar A: Low density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals. Arteriosclerosis 9:604-613, 1989
41. Krauss RM, Burke DJ: Identification of multiple subclasses of plasma low-density lipoproteins in normal humans. J Lipid Res 23:97-104, 1982
42. Knudsen P, Eriksson J, Lahdenpera S, Kahri J, Groop L, Taskinen M-R, the Botnia Study Group: Changes of lipolytic enzymes cluster with insulin resistance syndrome. Diabetologia 38:48-53, 1995
43. Chen Y-D, Facchini F, Landau C, Hollenbeck CB, Reaven GM: Plasma post-heparin lipoprotein lipase activity is decreased in normal individuals who are resistant to insulin-mediated glucose uptake. Endocrinol Metab 1:153-158, 1994
44. Taskinen M-R: Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 6:153-160, 1995
45. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen M-R: Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40:454-462, 1997
46. Lagrost L, Gambert P, Lallemant C: Combined effects of lipid transfers and lipolysis on gradient gel patterns of human plasma LDL. Arterioscler Thromb 14:1327-1336, 1994
47. Lahdenpera S, Syvanne M, Kahri J, Taskinen M-R: Regulation of low density particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 39:453-461, 1996
48. , McNamara JR, Jenner JL, Li Z, Wilson WF, Schaefer EJ: Change in LDL: particle size is associated with plasma triglycerides concentration. Arterioscler Thromb 12:1284-1290, 1992
49. Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ: Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia: reversal toward normal with bezafibrate treatment. J Clin Invest 74:470-482, 1984
50. Riemens SC, van Tol A, Scheek LM, Dullart RP: Plasma cholesteryl ester transfer and hepatic lipase activity are related to high-density lipoprotein cholesterol in association with insulin resistance in type 2 diabetic and non-diabetic subjects. Scand J Clin Lab Invest 61:1-9, 2001